Investigating the role of microbiota in small-intestine neuroendocrine tumors
Official title: Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors
Run by Hospices Civils de Lyon · NCT06624865 · Data updated 2026-11-12
This study is trying to see how the bacteria in the gut might affect the growth of small-intestine neuroendocrine tumors in people.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon, France) |
| Status | Recruiting |
| Started | November 5, 2024 |
| Main results expected | October 2029 |
| Study ends | October 2029 |
| Registry record updated | April 4, 2025 |
| Trial ID | NCT06624865 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have one or more small-intestine neuroendocrine tumors and are scheduled for surgery.
✕Probably not a fit
Patients with poorly differentiated neuroendocrine carcinoma, non-intestinal NETs, or mixed tumors, as well as pregnant or breastfeeding women, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore how the microenvironment, particularly the microbiota, influences the development of small-intestine neuroendocrine tumors, which are often found in the terminal ileum and lack identified driver mutations. Participants will undergo blood and stool sampling to gather data on their microbiota and tumor characteristics. The study seeks to enhance understanding of tumorigenesis in these specific tumors, potentially leading to new insights in treatment approaches.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the role of microbiota in tumor development, potentially leading to novel therapeutic strategies for patients with small-intestine neuroendocrine tumors.
How similar studies have gone: While the specific approach of examining microbiota in small-intestine neuroendocrine tumors may be novel, similar studies investigating the role of microbiota in other cancers have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with one or more small-intestine neuroendocrine tumor with indication of surgery * Patient with consent for the collection, storage and reuse of data associated with his/her disease * Age ≥ 18 years at the time of inclusion * Non-objection statement obtained for participation in the study Exclusion Criteria: * Patients with poorly differentiated neuroendocrine carcinoma or NET (neuroendocrine tumors) of non-intestinal origin or mixed tumors (MiNEN) * Pregnant, parturient or breast-feeding women * Minors * Persons deprived of liberty by judicial or administrative decision * Adults under legal protection (guardianship, curatorship)
Where it's running
-
Edouard Herriot University Hospital
Lyon, France, France Recruiting
Study contacts
- Study coordinator: Thomas WALTER, MD, PhD
- Email: thomas.walter@chu-lyon.fr
- Phone: 0472117398
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.